Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hUCMSCs + hCBMNCs
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Parenteral
01
Overview
hUCMSCs + hCBMNCs is a combination cell therapy consisting of human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs), developed by Shenzhen Beike Biotechnology. This therapeutic approach combines the immunomodulatory and regenerative properties of mesenchymal stem cells with the hematopoietic and angiogenic potential of cord blood mononuclear cells. The combination is designed to modulate immune responses and enhance angiogenesis. In models of cisplatin-induced acute kidney injury, it has demonstrated the ability to suppress HMGB1 expression and inhibit apoptosis by reducing the Bax/Bcl-2 ratio. The therapy is primarily being investigated for the treatment of premature ovarian failure (POF) in combination with hormone replacement therapy, as well as for acute kidney injury and burn injuries.
- Other names
- human umbilical cord mesenchymal stem cells and human cord blood mononuclear cellshUCMSCs and hCBMNCs
Beyond the preview
Go deeper on hUCMSCs + hCBMNCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hUCMSCs + hCBMNCs.